Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 208

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 208
---
 “Transaction Committee”), has unanimously determined that the Contemplated Transactions are in the best
interests of the Company and the Shareholders;

AND WHEREASin August 2024, the Company began a strategic
re-prioritization, and, in connection therewith, it has undertaken and continues to undertake the discontinuance and orderly wind-up of its business and operations,
including (i) concluding all research and development activities; (ii) disposing of or licensing-out all of its existing intellectual property and assets with a view of monetizing on those assets
with the ultimate objective of distributing all such proceeds to its shareholders; (iii) in connection with the foregoing, laying off nearly all of its workforce; and (iv) other activities consistent with the cessation of business
operations (collectively, the “Discontinuance”);

AND WHEREAS the Distribution is being made as part of the Discontinuance
pursuant to the terms hereof;

AND WHEREAS the Board of Directors has approved the entering into of this Agreement and the consummation of the
transactions contemplated herein and unanimously determined to recommend approval of the Arrangement by the Shareholders on the terms and subject to the conditions contained herein;

A-4

NOW THEREFORE THIS AGREEMENT WITNESSESthat the Parties (as hereinafter defined) hereby covenant and agree as follows: ARTICLE 1 INTERPRETATION

| 1.1 | Definitions |

In this Agreement (including the Schedules and the recitals hereto), unless the context otherwise requires:

| (a) | “Acceptable Confidentiality Agreement” means a confidentiality agreement entered into after                                                                                                                                                  
 the date hereof with the Company on customary terms that (a) include non-use and confidentiality covenants, customary exclusions from the definition of “Confidential Information,” and obligations to protect and restrict disclosure       
 of confidential information at least to a commercially reasonable standard and reasonably acceptable to Purchaser (it being understood that such agreement need not contain any “standstill” or similar provisions or otherwise prohibit the 
 making of any Acquisition Proposal), and (b) do not prohibit the Company from providing any information to the Purchaser in accordance with Article 6;                                                                                       |

| (b) | “Accounting Firm” has the meaning set out in Section 2.8(e); |

| (c) | “Acquisition Proposal” means, other than the Contemplated Transactions or any Permitted                                                                                                                                                                  
 Disposition, any offer, proposal, inquiry or public